• Versant-backed Bright Peak sets a date to bring its IL-2 into the clinic - but all eyes are on an IPO after latest mega-round drops

    6 days ago - By San Diego Biotechnology

    Just under a year after securing its first venture round, a Versant-backed startup has pulled in a massive Series B haul to create designer cytokines -and it seems as though CEO Fredrik Wiklund is keeping the S-1 paperwork in his back pocket. Bright Peak Therapeutics unveiled a $107 million...
    Read more ...